Erasca, Inc. Unrecognized Tax Benefits that Would Impact Effective Tax Rate
Erasca, Inc. (ERAS) had Unrecognized Tax Benefits that Would Impact Effective Tax Rate of $6.00 million as of 2025-12-31, per its 10-K filed 2026-03-12.
Financial Statements › Notes › Income Taxes › Income Tax Uncertainties
us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate · last filed 2026-03-12
- 2025-12-31: Unrecognized Tax Benefits that Would Impact Effective Tax Rate $6.00M.
- 2024-12-31: Unrecognized Tax Benefits that Would Impact Effective Tax Rate $5.00M.
- 2023-12-31: Unrecognized Tax Benefits that Would Impact Effective Tax Rate $3.80M.
- 2022-12-31: Unrecognized Tax Benefits that Would Impact Effective Tax Rate $2.50M.
| Period end | Unrecognized Tax Benefits that Would Impact Effective Tax Rate |
|---|---|
| 2025-12-31 | $6.00M 10-K · filed 2026-03-12 |
| 2024-12-31 | $5.00M 10-K · filed 2025-03-20 |
| 2023-12-31 | $3.80M 10-K · filed 2024-03-27 |
| 2022-12-31 | $2.50M 10-K · filed 2023-03-23 |
| 2021-12-31 | $1.10M 10-K · filed 2022-03-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |